Correlation Between Protalix Biotherapeutics and Checkpoint Therapeutics

Can any of the company-specific risk be diversified away by investing in both Protalix Biotherapeutics and Checkpoint Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protalix Biotherapeutics and Checkpoint Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Protalix Biotherapeutics and Checkpoint Therapeutics, you can compare the effects of market volatilities on Protalix Biotherapeutics and Checkpoint Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protalix Biotherapeutics with a short position of Checkpoint Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protalix Biotherapeutics and Checkpoint Therapeutics.

Diversification Opportunities for Protalix Biotherapeutics and Checkpoint Therapeutics

-0.13

Correlation Coefficient

Protalix Biotherapeutics  Checkpoint Therapeutics

Good diversification

The 3 months correlation between Protalix and Checkpoint is -0.13. Overlapping area represents the amount of risk that can be diversified away by holding Protalix Biotherapeutics and Checkpoint Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Checkpoint Therapeutics and Protalix Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protalix Biotherapeutics are associated (or correlated) with Checkpoint Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Checkpoint Therapeutics has no effect on the direction of Protalix Biotherapeutics i.e., Protalix Biotherapeutics and Checkpoint Therapeutics go up and down completely randomly.

Pair Corralation between Protalix Biotherapeutics and Checkpoint Therapeutics

Considering the 90-day investment horizon Protalix Biotherapeutics is expected to generate 0.39 times more return on investment than Checkpoint Therapeutics. However, Protalix Biotherapeutics is 2.57 times less risky than Checkpoint Therapeutics. It trades about 0.18 of its potential returns per unit of risk. Checkpoint Therapeutics is currently generating about 0.06 per unit of risk. If you would invest  183.00  in Protalix Biotherapeutics on December 27, 2024 and sell it today you would earn a total of  75.50  from holding Protalix Biotherapeutics or generate 41.26% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Protalix Biotherapeutics  vs.  Checkpoint Therapeutics

Protalix Biotherapeutics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Checkpoint Therapeutics

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Checkpoint Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Checkpoint Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Protalix Biotherapeutics and Checkpoint Therapeutics

The main advantage of trading using opposite Protalix Biotherapeutics and Checkpoint Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protalix Biotherapeutics position performs unexpectedly, Checkpoint Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Checkpoint Therapeutics will offset losses from the drop in Checkpoint Therapeutics' long position.

The idea behind Protalix Biotherapeutics and Checkpoint Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.